摘要
生命质量作为患者健康产出评价的重要指标,越来越多的被临床研究及药物经济学评价采纳。中医生命质量评价量表(CQ-11D)及其配套使用的健康效用积分算法体系是遵循国际量表开发程序,以中医理论和中医健康观为指导思想在借鉴、参考国内外生命质量量表及健康效用积分体系构建理论和方法的基础上,经德尔菲法专家咨询和带有生存时间的离散选择实验(DCETTO)调查形成。中医生命质量评价量表(CQ-11D)由中医生命质量评价量表指标和中医生命质量评价量表健康效用积分体系两部分构成,主要用于测量中医干预及一般人群生命质量健康效用评价,为医疗机构临床决策部门、卫生经济评估机构、卫生政策制定及决策机构、科研机构和新药注册研发单位提供决策依据。
As an important evaluation indicator of patients’health status,quality of life is frequently adopted by clinical research and pharmacoeconomic evaluation.The development of the Chinese Medicinal Quality of Life scale and its health utility scoring system followed the international scale development procedure.There are two parts of the Chinese medicine Quality of life-11Dimensions(CQ-11D),the index of CQ-11D and the health utility score system of CQ-11D.The construct of CQ-11D was based on the principles and theories of traditional Chinese medicine.The use of the Delphi expert consultation and discrete choice experiment with survival time(DCETTO)investigation was referred to the domestic and foreign quality of life scale and health utility score system construction theory and methods.It is mainly used to measure the quality of life and health utility of patients with traditional Chinese medicine intervention or the general population.The results will support decision-making for clinical decision-making departments of medical institutions,health economic evaluation institutions,health policy-making and decision-making institutions,scientific research institutions,and new drug registration and research institutions.
作者
朱文涛
高海亮
张梦培
史录文
陶立波
陈英耀
施李正
于长禾
韩晟
李顺平
潘婕
ZHU Wen-Tao;GAO Hai-Liang;ZHANG Meng-Pei;SHI Lu-Wen;TAO Li-Bo;CHEN Ying-Yao;SHI Li-Zheng;YU Chang-He;HAN Sheng;LI Shun-Ping;PAN Jie(School of Management,Beijing University of Chinese Medicine,Beijing 100029,China;Shouyao Holdings(Beijing)Co.,Ltd.,Beijing 102611,China;School of pharmacy,Peking University,Beijing 100191,China;International Research Center for Medicinal Administration,Peking University,Beijing 100191,China;Department of Health Policy and Management,Peking University Health Science Center,Beijing 100191,China;School of Public Health,Fudan University,Shanghai 200032,China;Department of Health policy management,Tulane University,Louisiana 70112,USA;Massage pain department,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Center for Health Management&Policy Research,School of Public Health,Cheeloo College of Medicine,Shandong University,Jinan 250012,China)
出处
《中国药物经济学》
2022年第5期16-20,45,共6页
China Journal of Pharmaceutical Economics